Evidence map›Paper›PMID 42476046›Full record

ArticleJournal of autoimmunity2026

Immunomodulatory effects of tacrolimus-loaded lipid-core nanocapsules in autoimmune hepatitis.

Graziela S Gomes, Cortney Cagle, William Li, Fernanda Visioli, Du Hanh Nguyen, Angelina Wei, Sruthika Macha, Eva Csizmadia, Alan Bonder, Vilas Patwardhan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Graziela S GomesDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Graduate Program in Pharmaceutical Sciences, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Núcleo de terapias nanotecnológicas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil. Electronic address: graziela.scheuer@gmail.com.
Cortney CagleDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: ccagle@bidmc.harvard.edu.
William LiDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: wli25@bidmc.harvard.edu.
Fernanda VisioliNúcleo de terapias nanotecnológicas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Faculty of Dentistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil. Electronic address: fevisioli@gmail.com.
Du Hanh NguyenDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: du-hanh.nguyen@stud.uke.uni-hamburg.de.
Angelina WeiDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: awei2@bidmc.harvard.edu.
Sruthika MachaDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: smacha1@bidmc.harvard.edu.
Eva CsizmadiaDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: ecsizmad@bidmc.harvard.edu.
Alan BonderDivision of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: abonder@bidmc.harvard.edu.
Vilas PatwardhanDivision of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: vpatward@bidmc.harvard.edu.
Silvia S GuterresNúcleo de terapias nanotecnológicas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Faculty of Dentistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Programa de Pós-Graduação em Farmácia, Faculdade de Farmácia, Universidade Federal da Bahia, Salvador, BA, Brazil. Electronic address: silvia.guterres@ufrgs.br.
Adriana R PohlmannNúcleo de terapias nanotecnológicas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Faculty of Dentistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil. Electronic address: adriana.pohlmann@ufrgs.br.
Luiza A FrankNúcleo de terapias nanotecnológicas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Faculty of Dentistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil. Electronic address: luiza.frank@ufrgs.br.
Maria Serena LonghiDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: mlonghi@bidmc.harvard.edu.

Funding

Alterations of aryl hydrocarbon receptor signaling in autoimmune hepatitisR01DK124408 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LONGHI, MARIA SERENA · 2020 to 2022
$1.2M
NIDDK NIH HHS R01 DK124408
6 · The paper itself

Abstract

Liver damage in autoimmune hepatitis (AIH) is perpetrated by T-effector lymphocytes that are not adequately restrained by regulatory T cells (Tregs). The goal of AIH treatment is to control inflammation and induce disease remission through administration of immunosuppressive drugs including corticosteroids, azathioprine, and, in difficult-to-treat cases, mycophenolate mofetil or tacrolimus (TAC). Despite TAC being a potent immunosuppressant, its use has been hampered by a narrow therapeutic window and systemic toxicity. In this study, we have tested the effects of lipid-core nanoformulations encapsulating TAC (NC-TAC) as a novel drug delivery system that would enable potentially favorable immunomodulatory effects compared with unencapsulated TAC. NC-TAC properties were assessed in vitro, in CD4 T cells and Tregs isolated from the peripheral blood of AIH patients and controls; and in vivo through a model of T cell-mediated liver injury induced by Concanavalin-A (Con-A) in NOD/scid/gamma mice, pre-emptively reconstituted with human CD4 T lymphocytes. Compared to unencapsulated TAC, NC-TAC favored a regulatory phenotype in CD4 T cells of AIH patients, enhanced the suppressive function and preserved AIH Treg phenotype in the presence of an inflammatory stimulus. Systemic administration of NC-TAC ameliorated liver injury in vivo, as indicated by decreased ALT levels, reduced lymphocyte infiltration on histology, and an increased frequency of intrahepatic CD4

Indexed as

Hepatitis, AutoimmuneImmunosuppressive AgentsNanocapsulesTacrolimusT-Lymphocytes, RegulatoryAdultAnimalsConcanavalin ADisease Models, AnimalFemaleHumansLipidsLiverMaleMiceMice, Inbred NODConcanavalin AImmunosuppressive AgentsLipidsNanocapsulesTacrolimusAutoimmune hepatitisLipid-core nanocapsulesRegulatory T cellsTacrolimus

Identifiers

PMID42476046
PMCPMC13428607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.